Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Antiandrogens  COVID-19 treatment studies for Antiandrogens  C19 studies: Antiandrogens  Antiandrogens   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 88% Improvement Relative Risk Ventilation 51% ICU admission 30% Recovery 88% Increase in Ct score 36% c19early.org/aa Hsieh et al. Antiandrogens for COVID-19 LATE Is late treatment with antiandrogens+multi-herbal formula beneficial for COVID-19? Prospective study of 260 patients in Taiwan (May - Aug 2021) Improved viral clearance with antiandrogens+multi-herbal formula (p=0.00015) Hsieh et al., Frontiers in Nutrition, doi:10.3389/fnut.2022.832321 Favors antiandrogen Favors control
Efficacy and Safety of Complementary Therapy With Jing Si Herbal Tea in Patients With Mild-To-Moderate COVID-19: A Prospective Cohort Study
Hsieh et al., Frontiers in Nutrition, doi:10.3389/fnut.2022.832321
Hsieh et al., Efficacy and Safety of Complementary Therapy With Jing Si Herbal Tea in Patients With Mild-To-Moderate.., Frontiers in Nutrition, doi:10.3389/fnut.2022.832321
Mar 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Prospective study of 260 hospitalized patients in Taiwan, 117 treated with herbal formula Jing Si Herbal Tea which includes antiandrogen glycyrrhiza glabra, showing improved recovery with treatment, with statistical significance for SpO2, Ct score, CRP, and Brixia score.
risk of death, 87.9% lower, RR 0.12, p = 0.13, treatment 0 of 117 (0.0%), control 4 of 143 (2.8%), NNT 36, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of mechanical ventilation, 51.1% lower, RR 0.49, p = 0.46, treatment 2 of 117 (1.7%), control 5 of 143 (3.5%), NNT 56.
risk of ICU admission, 30.2% lower, RR 0.70, p = 0.76, treatment 4 of 117 (3.4%), control 7 of 143 (4.9%), NNT 68.
risk of no recovery, 87.9% lower, RR 0.12, p = 0.13, treatment 0 of 117 (0.0%), control 4 of 143 (2.8%), NNT 36, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
relative increase in Ct score, 36.1% better, RR 0.64, p < 0.001, treatment mean 8.14 (±4.9) n=117, control mean 5.2 (±6.99) n=143.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hsieh et al., 14 Mar 2022, prospective, Taiwan, peer-reviewed, 7 authors, study period 1 May, 2021 - 31 August, 2021, this trial uses multiple treatments in the treatment arm (combined with multi-herbal formula) - results of individual treatments may vary.
Contact: drbfci@yahoo.com.tw.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAntiandrogensAll
Abstract: ORIGINAL RESEARCH published: 14 March 2022 doi: 10.3389/fnut.2022.832321 Efficacy and Safety of Complementary Therapy With Jing Si Herbal Tea in Patients With Mild-To-Moderate COVID-19: A Prospective Cohort Study Po-Chun Hsieh 1 , You-Chen Chao 2,3 , Kuo-Wang Tsai 4 , Chung-Hsien Li 2 , I-Shiang Tzeng 4 , Yao-Kuang Wu 3,5* and Cheng Yen Shih 6 1 Department of Chinese Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan, Department of Internal Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan, 3 School of Medicine, Tzu Chi University, Hualien, Taiwan, 4 Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan, 5 Division of Pulmonary Medicine, Department of Internal Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan, 6 Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan 2 Edited by: Vijay Kumar Bhardwaj, Institute of Himalayan Bioresource Technology (CSIR), India Reviewed by: Daniela Calina, University of Medicine and Pharmacy of Craiova, Romania Bhanu Sharma, Institute of Himalayan Bioresource Technology (CSIR), India *Correspondence: Yao-Kuang Wu drbfci@yahoo.com.tw Specialty section: This article was submitted to Clinical Nutrition, a section of the journal Frontiers in Nutrition Received: 09 December 2021 Accepted: 24 January 2022 Published: 14 March 2022 Citation: Hsieh P-C, Chao Y-C, Tsai K-W, Li C-H, Tzeng I-S, Wu Y-K and Shih CY (2022) Efficacy and Safety of Complementary Therapy With Jing Si Herbal Tea in Patients With Mild-To-Moderate COVID-19: A Prospective Cohort Study. Front. Nutr. 9:832321. doi: 10.3389/fnut.2022.832321 Frontiers in Nutrition | www.frontiersin.org Background: Since late 2019, there has been a global COVID-19 pandemic. To preserve medical capacity and decrease adverse health effects, preventing the progression of COVID-19 to severe status is essential. Jing-Si Herbal Tea (JSHT), a novel traditional Chinese medicine formula was developed to treat COVID-19. This study examined the clinical efficacy and safety of JSHT in patients with mild-to-moderate COVID-19. Methods: In this prospective cohort study, we enrolled 260 patients with mild-to-moderate COVID-19. The enrolled patients were divided into the JSHT (n = 117) and control (n = 143) groups. Both groups received standard management. The JSHT group was treated with JSHT as a complementary therapy. Results: Compared with standard management alone, JSHT combined with standard management more effectively improved the reverse transcription–polymerase chain reaction cycle threshold value, C-reactive protein level, and Brixia score in the adult patients with mild-to-moderate COVID-19, especially in the male and older patients (those aged ≥60 years). The results revealed that the patients treated with JSHT combined with standard management had 51, 70, and 100% lower risks of intubation, Medisave Care Unit admission, and mortality compared with those receiving standard management only. Conclusions: JSHT combined with standard management more effectively reduced the SARS-CoV-2 viral load and systemic inflammation and alleviated lung infiltrates in the patients with mild-to-moderate COVID-19, especially in the male and older patients (those aged ≥60 years). JSHT combined with standard management may prevent critical status and mortality in patients with mild-to-moderate..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit